Pharmacokinetics of intact lipid nanocapsules using new quantitative FRET technique

Heurtault, 2002, A novel phase inversion-based process for the preparation of lipid Nanocarriers, Pharm. Res., 19, 875, 10.1023/A:1016121319668 Roger, 2009, Lipid nanocarriers improve paclitaxel transport throughout human intestinal epithelial cells by using vesicle-mediated transcytosis, J. Control. Release, 140, 174, 10.1016/j.jconrel.2009.08.010 Urimi, 2022, Structural characterization study of a lipid Nanocapsule formulation intended for drug delivery applications using small-angle scattering techniques, Mol. Pharm., 19, 1068, 10.1021/acs.molpharmaceut.1c00648 Kaeokhamloed, 2021, New in vitro coculture model for evaluating intestinal absorption of different lipid nanocapsules, Pharmaceutics., 13, 10.3390/pharmaceutics13050595 Peltier, 2006, Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules, Pharm. Res., 23, 1243, 10.1007/s11095-006-0022-2 Ramadan, 2011, Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study, Int. J. Nanomedicine Pensel, 2015, Cystic echinococcosis therapy: Albendazole-loaded lipid nanocapsules enhance the oral bioavailability and efficacy in experimentally infected mice, Acta Trop., 10.1016/j.actatropica.2015.09.016 Amara, 2018, Praziquantel–lipid nanocapsules: an oral nanotherapeutic with potential Schistosoma mansoni tegumental targeting, Int. J. Nanomedicine, 13, 4493, 10.2147/IJN.S167285 Singh, 2020, PEGylated liposomes as an emerging therapeutic platform for oral nanomedicine in cancer therapy: in vitro and in vivo assessment, J. Mol. Liq., 303, 10.1016/j.molliq.2020.112649 Menzel, 2018, In vivo evaluation of an oral self-emulsifying drug delivery system (SEDDS) for exenatide, J. Control. Release, 277, 165, 10.1016/j.jconrel.2018.03.018 Carreño, 2020, Semi-mechanistic pharmacokinetic modeling of lipid core nanocapsules: understanding quetiapine plasma and brain disposition in a neurodevelopmental animal model of schizophrenia, J. Pharmacol. Exp. Ther., 375, 49, 10.1124/jpet.120.000109 Guo, 2020, A pharmacokinetics primer for preclinical nanomedicine research, 109 Yang, 2021, FRET Ratiometric Nanoprobes for nanoparticle monitoring, Biosensors., 11, 505, 10.3390/bios11120505 Roger, 2017, Lipid nanocapsules maintain full integrity after crossing a human intestinal epithelium model, J. Control. Release, 253, 11, 10.1016/j.jconrel.2017.03.005 Bonnet, 2021, Organic nanoparticle tracking during pharmacokinetic studies, Nanomedicine., 16, 10.2217/nnm-2021-0155 Partikel, 2019, Effect of nanoparticle size and PEGylation on the protein corona of PLGA nanoparticles, Eur. J. Pharm. Biopharm., 141, 70, 10.1016/j.ejpb.2019.05.006 Suk, 2016, PEGylation as a strategy for improving nanoparticle-based drug and gene delivery, Adv. Drug Deliv. Rev., 10.1016/j.addr.2015.09.012 Vonarbourg, 2006, Parameters influencing the stealthiness of colloidal drug delivery systems, Biomaterials., 27, 4356, 10.1016/j.biomaterials.2006.03.039 Kilin, 2014, Counterion-enhanced cyanine dye loading into lipid nano-droplets for single-particle tracking in zebrafish, Biomaterials., 35, 4950, 10.1016/j.biomaterials.2014.02.053 Lainé, 2014, Conventional versus stealth lipid nanoparticles: formulation and in vivo fate prediction through FRET monitoring, J. Control. Release, 10.1016/j.jconrel.2014.05.042 Toprak, 2016, Fluorescence study on the interaction of human serum albumin with Butein in liposomes, Spectrochimica Acta - part a: molecular and biomolecular, Spectroscopy., 154, 108 Seyedi, 2021, Fluorescence emission quenching of RdB fluorophores in attendance of various blood type RBCs based on stern-Volmer formalism, Spectrochim. Acta A Mol. Biomol. Spectrosc., 248, 10.1016/j.saa.2020.119237 Vergori, 2016, Low concentration of ethanol favors progenitor cell differentiation and neovascularization in high-fat diet-fed mice model, Int. J. Biochem. Cell Biol., 78, 43, 10.1016/j.biocel.2016.07.004 U.S. Food and Drug Administration, 2020 EMA Nishiya, 1995, Mechanistic study on toxicity of positively charged liposomes containing Stearylamine to blood, Artif. Cells Blood Substit. Biotechnol., 23, 505, 10.3109/10731199509117966 Groo, 2015, In vivo evaluation of paclitaxel-loaded lipid nanocapsules after intravenous and oral administration on resistant tumor, Nanomedicine., 10, 589, 10.2217/nnm.14.124 Morille, 2010, Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting, Biomaterials., 10.1016/j.biomaterials.2009.09.044 Basile, 2012, Serum-stable, long-circulating paclitaxel-loaded colloidal carriers decorated with a new amphiphilic PEG derivative, Int. J. Pharm., 426, 231, 10.1016/j.ijpharm.2012.01.038 Ichihara, 2011, Anti-PEG IgM response against PEGylated liposomes in mice and rats, Pharmaceutics., 3, 1, 10.3390/pharmaceutics3010001 Ishida, 2008, Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes, Int. J. Pharm., 354, 56, 10.1016/j.ijpharm.2007.11.005 Hashimoto, 2015, Relationship between the concentration of anti-polyethylene glycol (PEG) immunoglobulin M (IgM) and the intensity of the accelerated blood clearance (ABC) phenomenon against PEGylated liposomes in mice, Biol. Pharm. Bull., 38, 417, 10.1248/bpb.b14-00653 Li, 2012, Accelerated blood clearance of pegylated liposomal topotecan: influence of polyethylene glycol grafting density and animal species, J. Pharm. Sci., 101, 3864, 10.1002/jps.23254 Hirsjärvi, 2013, Effect of particle size on the biodistribution of lipid nanocapsules: comparison between nuclear and fluorescence imaging and counting, Int. J. Pharm., 453, 594, 10.1016/j.ijpharm.2013.05.057 Lee, 2010, The effects of particle size and molecular targeting on the intratumoral and subcellular distribution of polymeric nanoparticles, Mol. Pharm., 7, 1195, 10.1021/mp100038h Hirsjärvi, 2013, Influence of size, surface coating and fine chemical composition on the in vitro reactivity and in vivo biodistribution of lipid nanocapsules versus lipid nanoemulsions in cancer models, Nanomedicine, 10.1016/j.nano.2012.08.005 Adhipandito, 2021, Atypical renal clearance of nanoparticles larger than the kidney filtration threshold, Int. J. Mol. Sci., 22, 10.3390/ijms222011182 Hoshyar, 2016, The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction, Nanomedicine., 11, 673, 10.2217/nnm.16.5 Pearson, 2014, Understanding nano-bio interactions to improve nanocarriers for drug delivery, MRS Bull., 39, 227, 10.1557/mrs.2014.9 Gabizon, 2002, Dose dependency of pharmacokinetics and therapeutic efficacy of Pegylated liposomal doxorubicin (DOXIL) in murine models, J. Drug Target., 10, 539, 10.1080/1061186021000072447 Wu, 2013, Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumors, Eur. J. Clin. Pharmacol., 69, 2073, 10.1007/s00228-013-1580-y Danaei, 2018, Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems, Pharmaceutics., 10, 10.3390/pharmaceutics10020057 Yuan, 2019, Physiologically based pharmacokinetic modeling of nanoparticles, J. Pharm. Sci., 108, 58, 10.1016/j.xphs.2018.10.037 Byun, 2020, Recent advances in physiologically based pharmacokinetic and pharmacodynamic models for anticancer nanomedicines, Arch. Pharm. Res., 43, 80, 10.1007/s12272-020-01209-2 Gabizon, 2003, Pharmacokinetics of Pegylated liposomal doxorubicin, Clin. Pharmacokinet., 42, 419, 10.2165/00003088-200342050-00002 Probst, 2006, Gender differences in the blood volume of conscious Sprague-Dawley rats, J. Am. Assoc. Lab. Anim. Sci., 45, 49 Gravier, 2014, FRET imaging approaches for in vitro and in vivo characterization of synthetic lipid nanoparticles, Mol. Pharm., 11, 3133, 10.1021/mp500329z Bouchaala, 2016, Integrity of lipid nanocarriers in bloodstream and tumor quantified by near-infrared ratiometric FRET imaging in living mice, J. Control. Release, 236, 57, 10.1016/j.jconrel.2016.06.027 Cayre, 2018, In vivo FRET imaging to predict the risk associated with hepatic accumulation of squalene-based prodrug nanoparticles, Adv. Healthc. Mater., 7, 10.1002/adhm.201700830 Davis, 2002, The origin of pegnology, Adv. Drug Deliv. Rev., 54, 457, 10.1016/S0169-409X(02)00021-2 Park, 2018, Impact of anti-PEG antibodies on PEGylated nanoparticles fate in vivo, J. Control. Release, 287, 257, 10.1016/j.jconrel.2018.09.014 Bahari, 2016, The impact of variables on particle size of solid lipid nanoparticles and nanostructured lipid carriers; A comparative literature review, Adv. Pharm. Bull., 6, 143, 10.15171/apb.2016.021 Park, 2021, Evolution of drug delivery systems: from 1950 to 2020 and beyond, J. Control. Release Blättler, 2006, High salt stability and protein resistance of poly(L-lysine)-g- poly(ethylene glycol) copolymers covalently immobilized via aldehyde plasma polymer interlayers on inorganic and polymeric substrates, Langmuir., 22, 5760, 10.1021/la0602766